CohBar Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS
11 janv. 2021 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model
09 déc. 2020 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at the Piper Sandler 32nd Annual Healthcare Conference
19 nov. 2020 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update
16 nov. 2020 16h01 HE
|
CohBar, Inc.
MENLO PARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Announce 2020 Third Quarter Financial Results and Provide Business Update on November 16, 2020
02 nov. 2020 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis
29 oct. 2020 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event
27 oct. 2020 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model
26 oct. 2020 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at the BIO-Europe Conference
15 oct. 2020 16h05 HE
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar’s CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference
08 oct. 2020 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...